C arriage of the apolipoprotein E (APOE) 4 allele (e4) is associated with increased b-amyloid accumulation, greater preclinical cognitive decline and increased risk for clinical disease progression and dementia when compared with other APOE allelic variants. 1 Carriage of APOE4 among cognitively normal (CN) older adults is associated with greater decline in verbal memory than e4 noncarriers, 2 but there is no strong evidence for cognitive impairment in e4 carriers compared with noncarriers from studies using cross-sectional designs. However, we and others have shown that it is possible to amplify e4 specific cognitive impairment in CN older adults through utilization of pharmacological challenge. For example, Pomara et al 3 reported slower recovery from memory impairment induced by an acute dose of lorazepam (0.5 and 1 mg) in e4 carriers aged between 60 and 75 years compared with matched noncarriers. We showed that an acute 2 mg dose of lorazepam given to middle aged (ie, 50 to 65 y) CN adults caused greater decline in verbal episodic memory and visuospatial memory/executive function in e4 carriers compared with noncarriers despite equivalent baseline performances. 4 Together these findings suggest that while e4 carriage in CN adults is not associated with cognitive impairment per se, deleterious effects of e4 on central nervous system (CNS) function are evident in the greater vulnerability to sedative drugs shown by e4 carriers. These data also show how acute pharmacological challenge may be used practically to study impending Alzheimer disease (AD) risk in CN adults.
Recently it has been proposed that allelic variation in translocase of the outer mitochondrial membrane 40 homolog (TOMM40) may provide information about AD risk complementary to that provided by APOE4. 5, 6 These variations of TOMM40 include short (S), long (L), and very long (VL) poly-T lengths, with APOE3/3 individuals having either an S/S, S/VL, or VL/VL poly-T repeats. Earlier studies indicated that APOE3/3 individuals with VL/VL developed AD earlier than individuals with shorter poly-T repeats. 5 A subgroup of APOE3/3 individuals with VL/VL TOMM40 poly-T lengths also showed decreased gray matter volume in the ventral posterior cingulate and medial ventral precuneus and reduced verbal memory compared with those APOE3/3 individuals with short TOMM40 poly-T lengths (S/S). 7 Despite these early findings, the extent of risk conferred by TOMM40 for disease progression generally and for CNS dysfunction specifically remains unclear. For example, reanalyses of AD risk cohorts whose APOE4 status was known using TOMM40 classification showed age-related effects of TOMM40 VL/VL independent of APOE with the TOMM40 effect occurring before age 60 and the APOE effect occurring after age 60. 8 However, other studies have either failed to show any benefit of TOMM40 in explaining AD risk 9 or have indicated opposite results with VL/VL decreasing rather than increasing AD risk. 10 In this context, acute challenge with lorazepam may provide a means for determining the extent to which reclassification of APOE4 allelic variation according to TOMM40 lengths can improve estimates of CNS vulnerability in CN adults. To date, there has been one small study testing this hypothesis, where an acute 0.5 or 1 mg lorazepam dose was administered to 8 older (aged 62 to 73 y) APOE3/3 adults with TOMM40 VL/VL and 6 with S/S. 11 Lorazepam-related decline in verbal memory from baseline was observed at 2.5 hours post dose for both 0.5 and 1 mg doses in both TOMM40 groups although the magnitude of decline for the long poly-T group was almost double that observed for the short poly-T group. The interaction with TOMM40 genotype detected at 2.5 hours after lorazepam challenge was not due to pharmacokinetic factors such as differences in plasma lorazepam concentrations. Thus, these preliminary findings suggest that poly-T variants of TOMM40 may modulate the negative effects of lorazepam on memory in cognitively unimpaired APOE3/3 older adults, independent of any influence from APOE4. However, the very small sample used in this study raises the concern that estimates of lorazepam-related cognitive impairment specific to TOMM40 may be unreliable. Support for this concern is found in conclusions drawn from other studies of APOE3/3 individuals that the VL/VL genotype conveys a low, not high, risk for AD, whereas S/VL and S/S genotypes increase risk for AD in individuals aged 76 and older and 77 years and older, respectively. 12 Nevertheless, given the importance of this question and the reliability of the lorazepam challenge, further exploration of TOMM40 related CNS vulnerability is warranted. Therefore, the first aim of the current study was to establish the sensitivity of the lorazepam challenge in older adults according to their APOE4 status and identify aspects of cognition most sensitive to this challenge using a lower (1 mg) dose than our previous study. The second aim was to reclassify the sample according to TOMM40 risk variants and determine the extent to which these variants may be differentially sensitive to lorazepam-induced cognitive decline.
METHODS Participants
Fifty-seven CN adults aged from 51 to 88, who had previously been APOE and TOMM40 genotyped as a part of our longitudinal study of aging 13, 14 participated in this study. All participants were from Maricopa County, most of whom reported having a first-degree relative with AD, denied memory concerns and were recruited through local newspaper advertisements. Participants understood that they would not receive information about their APOE and TOMM40 genotype and were screened using a complete medical history, a structured psychiatric interview for Diagnostic and Statistical Manual of Mental Disorders III-Revised neurological examination, the Folstein Mini-Mental State Examination (MMSE), 15 and the Hamilton Depression Rating Scale (HAM-D, 17 item version). 16 Exclusion criteria were significant medical, psychiatric, or neurological illnesses (eg, impaired liver or kidney function, prior stroke, traumatic brain injury, memory impairment, cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar disorder, a psychoactive substance use disorder, or current major depression). For this study, participants with known allergy to benzodiazepines, current use (within the previous 4 wk) of benzodiazepines or other medications known to interact with lorazepam, concurrent use of sedating antihistamines, or current use of stimulant medications were excluded. Inclusion criteria were a score of 28 or more on the MMSE and <10 on the HAM-D. All participants gave written informed consent and study protocols were approved by the Mayo Clinic institutional review board.
Outcome Measures
The main outcome measure was the Groton Maze Learning Test (GMLT) 17 total errors, which measures visuospatial memory and executive function using a maze learning paradigm. In this task, the participant is shown a 10Â 10 grid of boxes on a computer screen. A 28-step pathway is hidden among these 100 possible locations. Each box represents move locations, and the grid refers to the box array (ie, 10Â10). Participants are required to find the hidden pathway guided by 4 search rules. These rules are: do not move diagonally, do not move more than 1 box (ie, do not jump), do not move back on the pathway, and return to the last correct location after an error. At each step only the most recently selected box is shown. Feedback is given with visual and auditory cues (green check marks and red crosses) to indicate whether the selected box is correct or incorrect. The head of path, or the last correct location, flashes with a green check when 2 errors are made in succession (failing to return errors). There are 20 well-matched alternate pathways available. The primary outcome is total number of errors made in attempting to learn the same hidden pathway over 5 consecutive trials. A decomposition of the total errors results in a learning efficiency factor (exploratory errors), which reflects how efficiently individuals are able to learn the maze, and an error monitoring factor (rule break errors), which reflects how well an individual monitors performance while learning the maze. 17 Secondary 17, 19 and, along with the GMLT, were selected because of their extensive use in psychopharmacological studies and demonstrated sensitivity to effects of benzodiazepines. [19] [20] [21] In the DET, the playing cards are all red and black jokers. The participant is asked to press the Yes key as soon as the card in the center of the screen flips over. The primary outcome is speed of performance. In the OCL, the playing cards are identical to those found in a deck of playing cards with the exception of the joker. The participant is asked whether the card currently being presented in the center of the screen was seen previously in this task. The participant responds by pressing the Yes or No key. Because no card has been presented yet, the first response is always No. The primary outcome is accuracy of performance. In the TBK, the playing cards are identical to those found in a deck of playing cards with the exception of the joker. The participant is asked whether the card currently being presented is the same as the one presented 2 cards previously. The participant responds by pressing the Yes or No key. Because no card has been presented yet, the first response is always No. The primary outcome is accuracy of performance.
Study Procedure
Participants completed cognitive testing before receiving a 1 mg dose of lorazepam and 2.5 and 5 hours after administration. The level of somnolence was also assessed at each time point with a computerized 10-point Likert scale (from 1 for "I feel fast asleep" to 10 for "I feel fully awake") for the question, "How sleepy are you feeling right now?"
Data Analysis
Demographics, baseline medical and psychiatric characteristics, and baseline cognitive outcome measures were compared between APOE3/4 and APOE3/3 groups using 2 sample t tests or w 2 tests or the Fisher exact tests when appropriate. The same characteristics were compared among the 5 TOMM40 groups using analysis of variance tests or w 2 tests or the Fisher exact tests when appropriate. The cognitive scores between 2.5 hour and baseline for all the participants were compared using paired t tests. The 2.5 and 5 hour cognitive scores were compared in groups (2 groups for APOE or 5 groups for TOMM40) using an analysis of covariance model with age and baseline scores as covariates. All analyses were executed using SAS 9.4.
RESULTS

Sample Characteristics
Baseline characteristics and demographics are summarized on Tables 1 and 2 . Groups (APOE3/4 vs. APOE 3/3; and S/S vs. S/L vs. S/VL vs. L/VL vs. VL/VL) were equivalent for age, sex, education, MMSE, HAM-D, somnolence, and baseline cognitive scores, although the APOE3/3 had a higher average body mass index (BMI) than the APOE3/4 group. When using nonparametric tests (Mann-Whitney), the difference in BMIs between groups was not statistically significant (P = 0.07).
Effect of e4 Carriage
At 2.5 hours after the 1 mg dose of lorazepam, the sample as a whole showed a statistically significant decline from baseline for measures of verbal memory, visual recognition memory, working memory, psychomotor processing speed, and visuospatial memory/executive function ( Table 3 ). The magnitude of lorazepam-induced cognitive change was significantly greater in the APOE3/4 group than in the APOE3/3 group for tests of visuospatial memory/ executive function (P = 0.03, effect size = 0.65) and working memory (P = 0.04, effect size = 0.59), but the decline was similar between groups for tests of verbal memory, visual recognition memory, and psychomotor processing speed ( Fig. 1 and Table 4) . A subanalysis of GMLT total errors showed the effect was driven primarily by exploratory errors (P = 0.01), that is, learning efficiency, rather than the rule break errors, that is, error monitoring (P = 0.28). At 5 hours after lorazepam challenge, we observed a trend for a persistent deficit in verbal memory and working memory scores for the APOE3/4 group compared with APOE3/3 (verbal memory: P = 0.06, effect size = 0.53; working memory: P = 0.12, effect size = 0.44), whereas the visuospatial memory/executive function score was similar and largely returned to baseline (Fig. 1) .
Effect of TOMM40
Results of the VL/VL and S/S comparison are shown in Table 5 
DISCUSSION
In this study, which differed from our previous study by using a lower dose (1 mg) lorazepam challenge and a slightly older population, we replicated our previous findings of significant declines in memory, working memory, psychomotor processing speed, and executive function in response to the lorazepam challenge among individuals who were cognitively unimpaired at baseline. We again found a greater decline on a test of visuospatial memory and executive function as measured by the GMLT at 2.5 hours post-lorazepam in APOE3/4 carriers than APOE3/3 carriers. We also found a greater decline in working memory as measured by the TBK in the APOE3/4 group than the APOE3/3 group at 2.5 hours post-lorazepam. In contrast to our previous study, we did not find an effect of lorazepam on verbal memory as measured by AVLT at 2.5 hours post-lorazepam challenge, but we did see a moderate effect of the drug 5 hours post dose, with the e4 group appearing to show a persistent memory deficit compared with the APOE3/3 group. The differential effect in episodic memory performance at 5 hours is consistent with that reported by Pomara et al 3 , who tested a group of similarly aged APOE e4 carriers and e4 noncarriers with a 1 mg lorazepam challenge. We were, however, unable to replicate the results of a more recent study by Pomara et al 11 that showed increased memory impairment in TOMM40 VL/ VL carriers compared with S/S individuals at 2.5 hours after a 1 mg dose lorazepam challenge. If anything, in our study the S/S subgroup performed slightly worse than VL/VL subgroup at 5 hours post-lorazepam challenge. The GMLT may be particularly sensitive to disruptions in learning occurring early in AD. In a study comparing the performance on GMLT between CN individuals and those with amnestic mild cognitive impairment, the amnestic mild cognitive impairment group showed a substantially less steep learning curve from the first to second learning trial of the maze. 22 Others have shown that worse GMLT scores correlate (P = 0.001) with smaller hippocampal volumes in CN individuals and a trend for correlation of hippocampal volume with AVLT (P = 0.06). 23 In replicating our previous results with GMLT in response to lorazepam among CN individuals, 4 this study provides further evidence that the GMLT may be a sensitive test when used with a lorazepam challenge to differentiate those cognitively unimpaired individuals who are at greater risk for AD. In addition, the fact that the effect on the GMLT was driven primarily by exploratory errors (ie, learning efficiency) suggests that the lorazepam-induced cognitive dysfunction in cognitively unimpaired individuals at greater risk for AD might, in part, be mediated by disruptions in learning similar to those seen early in AD.
Although it is difficult to find cross-sectional associations with amyloid and cognitive test scores, 23 the combination of Ab and APOE4 has been associated with longitudinal cognitive decline in preclinical AD. 24 b-amyloid deposition has also been associated with decreased prefrontal functional MRI activation with greater working memory loads in cognitively unimpaired elderly. 25 We had amyloid imaging in 12 of the 57 study participants, and, not surprisingly, in this subset we found significantly greater amyloid uptake in the APOE3/4 than APOE3/3 individuals. Others have examined cerebrospinal fluid levels of Ab associations with APOE4 and TOMM40 variants, demonstrating significant reductions in Ab 1 to 42 levels in APOE4 carriers compared with non-e4 carriers and no such differences across TOMM40 variants. 26 Our findings suggest that the low dose lorazepam challenge may be unmasking occult disease associated b-amyloid deposition in frontal lobes, which is more closely associated with APOE4 carriage than TOMM40 poly-T variants; this may be disrupting frontal-hippocampal circuits that underlie working memory and episodic memory. 27, 28 One other important issue arising from this study is that lorazepam is often prescribed to elderly individuals, 29 and benzodiazepines may increase risk for dementia, 30 although the data on benzodiazepine and risk of dementia is conflicting. 31, 32 Although this study did not address long-term impact, our results are consistent with the view that even short-term use of lorazepam could unmask cognitive difficulties in at-risk individuals. For example, when the AVLT scores are translated into age-normed scores, the average baseline scores for the group as a whole are high end of average, while the scores at 2.5 hours post-lorazepam challenge reflect a 1.3 SD decline to low end of average, which is a clinically significant difference. Clinicians should therefore weigh the benefit of reducing anxiety symptoms against the risk of worsening cognitive function in elderly who are at highest risk of AD, particularly if the anxiety being treated is in response to subtle cognitive decline. Pharmacogenomics testing is increasingly used to guide medication selection. 33 Further study specifically designed to compare prescribing practices and patient outcomes of providers who did or did not know the patients' APOE genotype is needed to determine whether APOE4 genotyping would be useful in guiding physicians away from prescribing benzodiazepines in at-risk patients. Conversely, if a CN patient does experience substantial cognitive problems in response to benzodiazepines, it may warrant further diagnostic evaluation. APOE testing is not currently recommended in CN individuals, 34 in part because there are no currently approved medical interventions to reverse the disease. More importantly, APOE4 carriers are not certain to develop dementia, nor are e4 noncarriers necessarily protected from it. Unfortunately, the public often misunderstand how to interpret the risk associated with APOE genotyping, 35 which may increase the chance for unintended consequences of gaining such information. 36 Therefore, we are not specifically recommending genotyping in the evaluation of a CN individual who experiences cognitive impairment brought on by benzodiazepines, but, depending on the clinical circumstances and confirmation of our results with a larger study, a standard evaluation, closer monitoring of cognition over time, avoidance of ongoing use of benzodiazepines and encouragement of healthy lifestyle changes may be appropriate.
We did not use a placebo control in this study, because the previous studies 3,4,11 all showed a clear separation from placebo, our participants were not aware of their genotype, and the primary comparison was between genotypes. Nonetheless, the lack of placebo is a limitation of this study as it is possible that a differential effect between genotypes could also occur in the placebo condition. We also did not measure blood levels of lorazepam, so we do not know whether some of the effects were due to differences in metabolism or possibly associated with differences in BMI. However, there was no difference in BMI between e4 carriers and noncarriers with our previous study that showed similar results, 4 and others have previously demonstrated that the interaction of genotype and lorazepam challenge had no associations with plasma lorazepam concentrations. 3, 11 Finally, this study is limited by its small sample size. The power to detect differences between the TOMM40 poly-T variant groups may have been insufficient given our small numbers in each of those groups, particularly as we did not have the power to separate those older than 76 years. We also may not have had sufficient power to detect differences in verbal memory between the APOE3/4 and APOE3/3 groups. After adjusting for multiple comparisons by controlling false discovery rate at 0.05 level, the significant results in decline from baseline for measures of verbal memory, visual recognition memory, working memory, psychomotor processing speed, and visuospatial memory/executive function for the group as a whole as depicted in Table 3 still hold. However, likely due to the small sample size of this study, the significant results in the APOE (Table 4 ) and TOMM40 (Table 5 ) group differences will not hold up to multiple comparisons. Given that the effect sizes for the significant results in Tables 4 and 5 are moderate to large (from 0.59 to 1.11), the difference between groups may still be clinically meaningful, but clearly further study with sufficient sample size to confirm the findings is needed.
In conclusion, lorazepam challenge is associated with acutely worsened cognition in all participants regardless of genotype, and working memory and visuospatial memory and executive function decline is more pronounced in APOE4 carriers than e4 noncarriers. The relative lack of differences in the TOMM40 poly-T variant groups may be due to lack of power and/or less of an association of TOMM40 allelic variations with amyloid pathology than APOE4. Next steps would ideally include a placebo controlled randomized trial stratified by the pertinent genotypes with sufficient sample size to account for multiple outcomes and comparisons. 
